Great Lakes Advisors LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,445 shares of the biopharmaceutical company’s stock after selling 73 shares during the period. Great Lakes Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Clearstead Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 197.6% during the third quarter. Clearstead Advisors LLC now owns 4,518 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 3,000 shares during the last quarter. Metis Global Partners LLC boosted its position in Alnylam Pharmaceuticals by 8.7% during the 3rd quarter. Metis Global Partners LLC now owns 4,288 shares of the biopharmaceutical company’s stock worth $759,000 after acquiring an additional 342 shares during the period. Arizona State Retirement System lifted its holdings in shares of Alnylam Pharmaceuticals by 0.5% during the 3rd quarter. Arizona State Retirement System now owns 33,973 shares of the biopharmaceutical company’s stock valued at $6,017,000 after buying an additional 153 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 12.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,479 shares of the biopharmaceutical company’s stock valued at $9,294,000 after buying an additional 5,980 shares during the last quarter. Finally, Privium Fund Management B.V. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $3,546,000. Institutional investors and hedge funds own 93.98% of the company’s stock.
Insider Buying and Selling at Alnylam Pharmaceuticals
In related news, Director Michael W. Bonney sold 30,000 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the completion of the transaction, the director now directly owns 16,029 shares of the company’s stock, valued at approximately $3,125,655. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.
Analysts Set New Price Targets
Alnylam Pharmaceuticals Price Performance
ALNY stock opened at $172.18 on Wednesday. The stock has a market capitalization of $21.61 billion, a price-to-earnings ratio of -41.59 and a beta of 0.43. Alnylam Pharmaceuticals, Inc. has a 52-week low of $148.10 and a 52-week high of $227.91. The company has a 50-day moving average of $183.65 and a two-hundred day moving average of $180.00.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- Conference Calls and Individual Investors
- Is the dip in Atlassian stock a sneaky buy opportunity?
- 3 Small Caps With Big Return Potential
- Caterpillar stock hits new highs; time to ring the register?
- Investing In Preferred Stock vs. Common Stock
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.